Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Senate Committee Releases Draft User Fee Bill as House Votes to Send Its Version to the Floor

  • Post author:PacConAdmin
  • Post published:May 18, 2022
  • Post category:Drug Industry Daily

The House Energy and Commerce Committee voted unanimously Wednesday to move its version of a bill to reauthorize the FDA’s prescription drug, generic drug, biosimilar and medical device user fee…

Continue ReadingSenate Committee Releases Draft User Fee Bill as House Votes to Send Its Version to the Floor

FDA Updates OOS Testing Principles in Revised Final Guidance

  • Post author:PacConAdmin
  • Post published:May 17, 2022
  • Post category:Drug Industry Daily

The FDA has revised its final guidance on investigating out-of-specification (OOS) drug test results, adding recommendations for evaluating results and revising outdated terminology. Source: Drug Industry Daily

Continue ReadingFDA Updates OOS Testing Principles in Revised Final Guidance

FDA Issues Final Guidance on Assessing User Fees Under GDUFA II

  • Post author:PacConAdmin
  • Post published:May 17, 2022
  • Post category:Drug Industry Daily

The FDA formalized user fee assessment changes under the Generic Drug User Fee Act of 2017 (GDUFA) in a final guidance released yesterday, adding a new section on refunds to…

Continue ReadingFDA Issues Final Guidance on Assessing User Fees Under GDUFA II

FDA Lifts Hold on Gilead Sciences’ Investigational HIV Drug Lenacapavir

  • Post author:PacConAdmin
  • Post published:May 17, 2022
  • Post category:Drug Industry Daily

The FDA has removed a clinical hold it placed on Gilead Sciences’ experimental HIV-1 drug lenacapavir in December 2021 because of quality concerns about the drug’s borosilicate glass vials. Source:…

Continue ReadingFDA Lifts Hold on Gilead Sciences’ Investigational HIV Drug Lenacapavir

FDA Says No to Generic Antidepressant Fluvoxamine as a COVID-19 Treatment

  • Post author:PacConAdmin
  • Post published:May 17, 2022
  • Post category:Drug Industry Daily

The FDA gave the generic antidepressant fluvoxamine a decisive thumbs-down as a treatment option for COVID-19 this week, only days after an influential independent nonprofit research panel recommended it. Source:…

Continue ReadingFDA Says No to Generic Antidepressant Fluvoxamine as a COVID-19 Treatment

FDA OKs Booster of Pfizer-BioNTech COVID-19 Vaccine for Kids Five to 11

  • Post author:PacConAdmin
  • Post published:May 17, 2022
  • Post category:Drug Industry Daily

The FDA has authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for children age five through 11 years. Source: Drug Industry Daily

Continue ReadingFDA OKs Booster of Pfizer-BioNTech COVID-19 Vaccine for Kids Five to 11

AstraZeneca’s Albuterol/Budesonide Combo Asthma Drug Drops Flare-ups in Study

  • Post author:PacConAdmin
  • Post published:May 16, 2022
  • Post category:Drug Industry Daily

The novel combination of albuterol and budesonide in AstraZeneca’s PT027 reduced the risk of severe asthma flare-ups by 27 percent in patients with moderate-to-severe asthma, according to results from a…

Continue ReadingAstraZeneca’s Albuterol/Budesonide Combo Asthma Drug Drops Flare-ups in Study

FDA Approves Eli Lilly’s Potential Blockbuster in Type 2 Diabetes

  • Post author:PacConAdmin
  • Post published:May 16, 2022
  • Post category:Drug Industry Daily

The FDA has approved Eli Lilly’s Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval marks the…

Continue ReadingFDA Approves Eli Lilly’s Potential Blockbuster in Type 2 Diabetes

Acella Pharmaceuticals Sued Over Recalled Thyroid Drug

  • Post author:PacConAdmin
  • Post published:May 16, 2022
  • Post category:Drug Industry Daily

Acella Pharmaceuticals is facing a potential class action lawsuit in a federal court in Georgia that claims its NP Thyroid hormone replacement drug is “worthless” and left one patient with…

Continue ReadingAcella Pharmaceuticals Sued Over Recalled Thyroid Drug

BridgeBio Sells Coveted Priority Review Voucher for $110M to Undisclosed Buyer

  • Post author:PacConAdmin
  • Post published:May 16, 2022
  • Post category:Drug Industry Daily

BridgeBio Pharma is offloading its rare pediatric disease priority review voucher (PRV) for $110 million to an undisclosed buyer. Source: Drug Industry Daily

Continue ReadingBridgeBio Sells Coveted Priority Review Voucher for $110M to Undisclosed Buyer
  • Go to the previous page
  • 1
  • …
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.